Masaru H. Oshita

发表

Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19

Y. Soo, G. Yancopoulos, D. Weinreich, 2022, International Journal of Infectious Diseases.